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Abstract
Introduction The present study determined whether late-
ischemia/early reperfusion therapy with the β1-adrenergic
receptor (AR) blocker esmolol and phosphodiesterase III
inhibitor milrinone reduced left ventricular (LV) myocardial
infarct size (IS).
Methods and Results In an ischemia/reperfusion rat model
(30-min ischemia/4-hr reperfusion), esmolol, milrinone or
esmolol + milrinone were intravenous (IV) infused over
10 min (from the last 5min of ischemia to the first 5min of
reperfusion). LV-IS were 48.9±8.9%, 41.5±5.4%, 25.8±
7.7% and 16.8±7.3% for saline, esmolol, milrinone, and
esmolol + milrinone, respectively (n=12/group). Esmolol +
milrinone further reduced LV-IS compared with esmolol or
milrinone alone (p<0.05). LV-IS-reduction induced by
esmolol + milrinone was eliminated in the presence of
protein kinase A-(PKA)-inhibitor (Rp-cAMPS) or Akt-
inhibitor (AKT 1/2 kinase inhibitor). In mixed rat ventricular
cardiomyocyte cultures, intra-ischemic application of esmo-
lol, milrinone or esmolol + milrinone reduced myocyte death
rates by 5.5%, 13.3%, and 16.8%, respectively, compared
with saline (p<0.01). This cell protective effect by esmolol +
milrinone was abrogated in the presence of PKA-inhibitor or
Akt-inhibitor. Esmolol, milrinone or esmolol + milrinone
increased myocardial PKA activity by 22%, 28% and 59%,
respectively, compared with saline (n=6, p<0.01). No non-
specific adverse effect of Rp-cAMPS on myocytes was
identified in a purified myocyte preparation during hypoxia/
re-oxygenation. Antiapoptotic pathways were assessed by
measuring myocardial phosphorylated Akt (pAkt) levels
combined with terminal dUTP nick-end labelling staining
analysis.Tenminutesfollowinginfusionofesmolol,milrinone
or esmolol + milrinone, there were 1.7-, 2.7-, and 6-fold
increase in tissue pAkt levels, respectively. This esmolol +
milrinone induced pAkt activation was abolished in the
presence of PKA inhibitor. Esmolol, milrinone and esmolol +
milrinone reduced myocyte apoptosis rates by 22%, 37% and
60%, respectively, compared with saline (p<0.01).
Conclusions Late-ischemia/early reperfusion therapy with
esmolol+milrinone additively reduces LV-IS associated
with robust activation of myocardial PKA and subsequent
Akt-antiapoptotic pathway.
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Introduction
While the translation of ischemic preconditioning to clinical
application remains unrealistic for patients with acute
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DOI 10.1007/s10557-011-6302-zmyocardial infarction (AMI), recent research in ischemic
postconditioning opens new opportunity for potentially
accessible clinical treatment for AMI. Reperfusion injury
salvage kinase (RISK) pathway has been implicated in the
postconditioning for infarct-size (IS) reduction [1, 2].
Among several potential mechanisms, Akt activation has
been implicated as one of the key signaling pathways
underling postconditioning mediated heart protection [1, 2],
although species difference has been reported [3]. The
mammalian heart possesses adrenopeptidergic neuropara-
crine system consisting of intrinsic cardiac adrenergic
(ICA) cells [4–6]. ICA cells synthesize and release
epinephrine and calcitonin gene-related peptide (CGRP),
stimulating myocardial β2-adrenoreceptor (β2-AR) and
CGRP-receptors [5, 6], both of which being coupled to
the adenylate cyclase-cAMP-dependent signaling pathway
[7–9]. Concomitant stimulation of cardiac β2-AR/CGRP-
receptors before ischemia or at the beginning of the
reperfusion confers robust IS-reduction [10]. This adreno-
peptidergic signaling is mediated through the activation of
cAMP-dependent PKA [10] which, in turn, activates Akt, a
powerful antiapoptotic signaling pathway [1, 2, 11, 12]. It is
conceivable that medications sharing similar distal signal-
ing mechanisms of β2-AR/CGRP-receptors may provide
alternatives for the receptor-mediated cardioprotection. For
instance, direct myocardial PKA activation with a phos-
phodiesterase (PDE) III inhibitor milrinone at reperfusion
may confer equivalent cardioprotection to that conferred by
β2-AR/CGRP-receptor stimulation, since milrinone is
known to activate PKA [13, 14]. High dose of β1-AR
blocker esmolol given at the onset of reperfusion reduces
LV-IS [15]. This cardioprotective effect is likely mediated,
in part, through the enhanced β2-AR signaling promoting
myocyte survival [11, 12], since at early reperfusion, there
is >100 fold increase in myocardial interstitial epinephrine
release [16] exerting unopposed myocardial β2-AR stimu-
lation in the presence of β1-AR blockade. Although, it has
been reported that intra-ischemic PKA activation with
milrinone reduces right ventricular IS in dogs [17], it has
not been demonstrated whether intra-ischemic/reperfusion
therapy with milrinone reduces LV-IS. Furthermore, the
mechanism underlying post-ischemia milrinone-induced
heart protection has not been elucidated. We have hypoth-
esized that cardiac PKA activation with the selective β1-AR
blocker esmolol in combination with milrinone at late-
ischemia/early reperfusion decreases LV-IS. The present
study had the following objectives: to determine if: 1) LV-
IS can be additively reduced by cardiac PKA activation
with combination therapy of esmolol + milrinone delivered
at the beginning of reperfusion, in a manner dependent of
PKA and Akt activation; 2) myocyte death rates can be
reduced by intra-ischemic treatment with esmolol +
milrinone in vitro, 3) combination therapy with esmolol +
milrinone additively enhance myocardial PKA and PKA-
dependentAktactivation;and4)esmolol+milrinone-induced
Akt activation results in reduced myocyte apoptosis during
ischemia/reperfusion.
Materials and methods
Effect of esmolol + milrinone on LV-IS-reduction The rat
AMI model consisted of 30-min ischemia and 4-hr
reperfusion [5, 6, 18]. Protocols for animal studies were
approved by the Institutional Animal Care and the Use
Committee of the University of Texas Medical Branch.
Saline, esmolol (10 μg/kg/min), milrinone (5 μg/kg /min)
or esmolol + milrinone were infused via the tail veins over
10-min (5-min before and after the onset of reperfusion, n=
12/group). Arterial blood pressure (BP) and heart rate (HR)
were monitored via an artery catheter (iWorx/CB Sciences,
Inc, Dover, NH). It should be noted that to avoid significant
hemodynamic changes, the milrinone dose applied in the
present study is only 1/10 of that recommended loading
dose for clinical heart failure treatment and esmolol dose is
1/5 of that maintenance dose for the treatment of clinical
supraventricular tachycardia. To test whether esmolol +
milrinone induced effect was dependent on PKA activation,
LV-IS was assessed in the animals (n=12) who received
PKA inhibitor Rp-cAMPS (2 mg/kg, infused at 10 min after
coronary artery occlusion) followed by infusion of esmolol +
milrinone. The effect of Rp-cAMPS alone on IS was tested in
8 animals. To determine whether esmolol’s effect was
mediated through the enhanced endogenous cardiac β2-AR
stimulation, the effect of esmolol on IS was tested in the
animals (n=8) pretreated with the selective β2-AR antagonist
ICI-118,551 (200 μg/kg/min for 5 min) infused at 10 min
after the onset of ischemia. To further test whether the
cardioprotective effect of esmolol + milrinone was dependent
on Akt activation, IS was assessed in a separate group of
animals (n=12) who received Akt inhibition with AKT 1/2
kinase inhibitor (Sigma, 2 mg/kg, infused at 10 min after the
onset of ischemia) followed by administration of esmolol +
milrinone. The effect of AKT 1/2 kinase inhibitor on IS was
also tested separately (n=8).
Effect of esmolol + milrinone on myocyte protection in
vitro To confirm the in vivo intra-ischemic myocyte-
protection of esmolol + milrinone, we studied their effects
in a well validated adult rat mixed cardiomyocyte culture
preparation [5, 6]. After 24 hr culture, hypoxia was induced
by layering mineral oil over media covering the cells for
2 hr followed by 60 min re-oxygenation. Saline, esmolol
(1 nmol/L), milrinone (4.7 μmol/L) or esmolol + milrinone
was individually applied to the myocyte culture at the
30 min after the onset of ischemia. The effects of esmolol +
224 Cardiovasc Drugs Ther (2011) 25:223–232milrinone on myocyte survival were also tested in the
presence of Rp-cAMPS (10 μmol/L) or AKT 1/2 kinase
inhibitor (10 μmol/L). Myocyte death rates were quantified
by counting trypan blue-stained cells and expressed as a
percentage of the total cells counted (n=8/group). The
examiner who counted cells was blinded to the treatment
assignments.
To determine whether Rp-cAMPS exerts any non-specific
effects on ventricular myocyte, we tested the effect of Rp-
cAMPS on isolated ventricular myocytes depleted with
ICA cells. This is an important issue, since in the intact
heart or cultured cardiocyte mixture, there are endogenous
and constitutive adrenopeptidergic neuroparacrine-to-
myocyte inputs (derived from ICA cells) via cAMP/PKA-
dependent signaling [4–6]. Removal of ICA cells from
myocytes allows direct assessment of the effect of Rp-
cAMPS on myocytes without introducing confounding
effect. In ICA cell-free myocyte preparation, we further
tested whether Rp-cAMPS specifically blocked the effect of
known PKA activators (ie, β2-AR agonist terbutaline plus
CGRP) [6, 10]. The ICA cell-free myocytes were prepared
by mechanical depletion of ICA cells from dissociated rat
ventricular cardiocytes using magnetic purification method
[4–6]. After 24-hr cell culture, saline, Rp-cAMPS
(100 μmol/L), or the combination of CGRP (5 μmol/L)
and β2-AR agonist terbutaline (10 nmol/L) were applied
individually to ICA cell-free myocyte culture at 30 min
after the onset of hypoxia. In addition, the effect of
terbutaline + CGRP was tested in the presence of Rp-
cAMPS applied 10-min before the administration of the
drugs. Myocyte death rate was quantified by counting
trypan blue-stained cells and expressed as a percentage of
the total cells counted (n=6/group).
Effect of esmolol + milrinone on myocardial PKA and
Akt In the same ischemia model, saline, esmolol, milrinone
or esmolol + milrinone were IV infused over 10-min (5 min
before and after the onset of reperfusion, n=6/group). Ten
minutes into the reperfusion, LV tissues just below the
ligation snare were removed and stored in liquid nitrogen
for PKA and Akt assay. To standardize tissue preparation,
the anterior half of LV myocardial tissue (3 mm below the
ligation) extending to the apex was removed for the
analysis. Tissue PKA activity was determined using a
SignaTECT cAMP-dependent PKA assay system (Prom-
ega, Madison, WI). Western blot was performed to detect
Akt activity (Ser 473). Dilution for anti-pAkt and anti-Akt
(Santa Cruz Biotechnology, Santa Cruz, CA) was 1:1000
[15]. To determine whether the Akt activation is dependent
on PKA signaling pathway, animals (n=4) were pretreated
with Rp-cAMPS (2 mg/kg IV) 10 min after the onset of
ischemia followed by the administration of esmolol +
milrinone. Then, myocardial pAkt activity was determined
as described above.
TUNEL staining Immunoflurosecent and terminal dUTP
nick-end labeling (TUNEL) were performed in 4 groups of
ischemic/reperfused rat hearts treated with saline, esmolol,
milrinone or esmolol + milrinone. The methods for tissue
preparation and TUNEL staining were described elsewhere
[6]. Tissues were harvested at 4 hr after reperfusion for
apoptosis determination. Adult rat cardiac myocyte is
binucleated [19]. It is possible that only one of nuclei of
myocyte exhibits TUNEL-positive staining when it under-
goes apoptosis at early stage. Since one (not necessarily
two) TUNEL-positive nuclei is required to define an
apoptotic myocyte, the % apoptotic cells/section was
estimated by counting the number of TUNEL-staining
nuclei divided by ½ total number of propidium iodide-
positive nuclei in 10 randomly selected fields (n=6 slides/
heart). Six hearts for each treatment group were studied. To
confirm that apoptotic nuclei are truly belongs to true
ventricular myocytes, additional TUNEL staining was
performed in conjunction with immunohistochemical co-
localization of myocyte-specific marker α-actinin using
DeadEnd Fluorometric TUNEL System Kit (Promega,
Madison, WI). Mouse anti-α-actinin (1:100 dilution,
Abcam Cambridge MA,) was used as the primary antibody
to counter label myocytes. Secondary antibody was Alexa
Fluor 568 goat anti-mouse IgG (H + L) (1:1000 dilution,
Invitrogen Corporation, Carlsbad, CA). TUNEL-positive
nuclei within counter-stained myocytes were analyzed from
control, esmolol, milrinone and esmolol + milrinone treated
groups. Ten randomly selected fields were analyzed for
each tissue section and six slides were countered for each
heart (n=6 hearts/group). The number of apoptotic myo-
cytes in control group was compared to esmolol, milrinone,
and esmolol + milrinone treated group.
Data analysis Two-way ANOVA (saline vs. milrinone in
the absence and presence of esmolol) was used for
analyzing LV-IS, PKA and Akt activation and apoptosis
in ischemia/reperfusion studies with the Bonferroni adjust-
ment for intra-group comparisons. All data are presented as
mean ± SD. The significance level α is 0.05.
Results
Effect of esmolol + milrinone on LV-IS and myocyte
protection Compared with saline control, 13%, 45% and
65% IS-reduction were observed in animals receiving
reperfusion treatment of esmolol, milrinone or esmolol +
milrinone, respectively (n=12/group, p<0.01, Fig. 1). IS-
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animals pretreated with the β2-AR antagonist ICI-118,551
which alone increased IS (p<0.05 n=8), compared with
saline (Fig. 1f). Esmolol + milrinone conferred 35% and
59% more IS reduction compared with milrinone or
esmolol alone, respectively (p<0.05). In the presence of
Rp-cAMPS or AKT 1/2 kinase inhibitor, esmolol +
milrinone conferred no reduction on IS. Rp-cAMPS or
Akt inhibitor alone increased IS, compared with saline
group (p<0.05, n=8, Fig. 1f). There were no significant
differences in animal weight and area-at-risk among all the
groups (data not shown). There was no significant change
in arterial BP following esmolol + milrinone infusion. A
6% HR reduction was observed at 6 min following the
completion of esmolol + milrinone infusion (Tables 1, 2,
3). There was no post-ischemic mortality in the animals
receiving esmolol, milrinone or esmolol + miltinone. The
mortality rates were 10%, 30% and 35% in saline,
Rp-cAMPS, and Akt-inhibitor groups, respectively. In
mixed myocyte cultures, treatment with esmolol, milri-
none and esmolol + milrinone reduced cell death rates by
5.5%, 13.3% and 16.8%, respectively, compared with
saline (n=8/group, p<0.01, Fig. 1). The myocyte death
rates of esmolol + milrinone group in the presence of
A B C
D E
** **
** *
**
Saline E M E + M
Rp-cAMPS
Rp-cAMPS
Saline E M E + M
**
** **
F
Saline
ICI
E E+M E+M
**
*
Akt-inhibitor
Akt-inhibitor
Rp-cAMPS Akt-inhibitor
Fig. 1 Panels A, B and C show representative cases of IS in the
animals treated with saline (a), esmolol + milrinone (E + M) (b) and
E + M in the presence of Rp-cAMPS (c). Infarcted tissue is indicated
with yellow color. Panel d shows the IS affected by the therapy with
esmolol, milrinone or E + M in the absence and presence of Rp-
cAMPS or AKT ½ kinase inhibitor (n=12/group). IS in E + M-treated
group is significantly smaller compared with all other groups (*: p<
0.05, **: p<0.01). Panel E: the effects of intra-ischemic application of
esmolol, milrinone or E + M in the absence and presence of Rp-
cAMPS or AKT 1/2 kinase inhibitor on myocyte death rates during
hypoxia/re-O2 in myocyte culture preparation (n=8/group). Panel f:
effects of β2-AR antagonist ICI-118,551 (ICI), Rp-cAMPS, or AKT-
inhibitor alone on IS, comparing with saline (n=8/group). Effects of
esmolol, milrinone and esmolol + esmolol in the presence of their
respective antagonists were plotted for comparison. Myocyte death
rate in E + M treated group is significantly lower compared with all
other groups (*: p<0.05, **: p<0.01)
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control (Fig. 1). In ICA cell-free myocyte preparation, the
effect of Rp-cAMPS on myocytes was not different from
that of saline during hypoxia/re-oxygenation (p=ns, n=6,
Fig. 2). The myocyte protective effect conferred by
terbutaline + CGRP was abolished in the presence of Rp-
cAMPS (Fig. 2).
Effect of esmolol + milrinone on myocardial PKA and Akt
activation Five min after completing infusion of esmolol,
milrinone or esmolol + milrinone, there was 22%, 28% and
59% increase in ischemic LV tissue PKA activity, respec-
tively, compared with control (Fig. 3). In parallel with PKA
changes, esmolol, milrinone and esmolol + milrinone
treatment increased pAkt levels in ischemic LV tissue by
1.7-, 2.7-, and 6-fold, respectively. There was no increase in
cardiac pAkt activity in those animals pretreated with Rp-
cAMPS. Compared with saline treatment, Rp-cAMPS or
esmolol + milrinone in the presence of Rp-cAMPS induced
0.8- and 0.9- fold pAkt changes (p=ns, Fig. 4).
Effect of esmolol + milrinone on myocyte apoptosis Early
reperfusion treatment of LV myocardium with esmolol,
milrinone or esmolol + milrinone reduced overall cardio-
cyte apoptosis by 23%, 37% and 60%, respectively,
compared with saline control (Fig. 5). Myocyte-specific
TUNE staining demonstrated 28%, 40% and 67% reduction
in apoptosis in esmolol, milrinone and esmolol + milrinone
treatment group, respectively, compared with saline control
(Fig. 5).
Discussion
We have demonstrated for the first time that brief IV
infusion of esmolol + milrinone at late-ischemia and
early-reperfusion (i.e., bridging from end of coronary
occlusion to re-canalization) confers robust additive LV-
IS-reduction. This cardioprotective effect is associated
with the activation of PKA/Akt-dependent antiapoptotic
signaling.
Effect of esmolol + milrinone on LV-IS Ischemic precondi-
tioning with milrinone reduces LV-IS in a canine reperfused
AMI model [14]. However, until proven otherwise, the
pharmacological ischemic preconditioning cannot generalize
the same mechanism and outcome when the same agent is
administered in ischemic postconditioning setting. The car-
dioprotective effect of intra-ischemic milrinone administration
has not been fully established. The cellular mechanisms
underlying milrinone-mediated ischemic postconditioning are
unknown. Inconsistent results have been published with
respect to the effects of intra-ischemic administration of
milrinone on the heart [17, 20]. Intra-ischemic milrinone
infusion in a non-reperfused canine AMI model failed to
reduce LV-IS [20]. In contrast, a recent study reported that
intra-ischemic milrinone infusion reduced right ventricular IS
in a canine ischemia-reperfusion model [17], although the
latter study provided no data on the effect of milrinone on LV-
IS [17]. The lack of milrinone-induced LV-IS-reduction in
non-reperfused AMI [20] could be explained by the lack of
reperfusion injury, a process that would have been effectively
targeted by milrinone. In an isolated perfused rabbit heart
model, milrinone had no effect on LV-IS [21]. This could be
due to the fact that isolated hearts already underwent a brief
episode of ischemia preconditioning during the heart isolation
procedure thereby blunting subsequent milrinone’s effect. The
Table 1 Hemodynamic changes following intravenous infusion of
esmolol + milrinone
Esmolol +
Milrinone
25-min into
ischemia (5-min
before reperfusion)
10-min after
completion
of esmolol +
milrinone infusion
P
HR 241±29 227±16 <0.01
Systolic BP 140±16 135±13 NS
Diastolic BP 120±5 110±6 NS
HR × BP 33636±2669 30661±1675 <0.01
Table 2 Hemodynamic changes following intravenous infusion of
esmolol
Esmolol 25-min into
ischemia (5-min
before reperfusion)
10-min after
completion of
esmolol infusion
P
HR 240±28 218±16 <0.01
Systolic BP 142±16 140±13 NS
Diastolic BP 120±8 116±6 NS
HR x BP 34080±2568 28340±1675 <0.01
Table 3 Hemodynamic changes following intravenous infusion of
milrinone
Milrinone 25-min into
ischemia (5-min
before reperfusion)
10-min after
completion of
milrinone infusion
P
HR 241±29 246±28 <0.05
Systolic BP 141±16 137±13 NS
Diastolic BP 120±5 115±6 NS
HR × BP 33980±2615 33702±2642 NS
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reperfusion administration of milrinone reduced LV-IS.
Furthermore, we demonstrated that early reperfusion admin-
istration of esmolol + milrinone conferred additive LV-IS-
reduction. The cell protective effect conferred by esmolol +
milrinone was confirmed in an isolated mixed myocyte
preparation in the present study. Endogenous epinephrine
derived from ICA cells confers significant myocardial
protection against reperfusion injury through β2-AR stimula-
tion [5, 6]. In consistent with this concept, the present study
demonstrated that esmolol’s IS-reduction is primarily medi-
ated via the enhancement of cardiac β2-AR signaling. It has
been demonstrated that myocardial interstitial epinephrine
levels can increase by >100 fold in the early coronary
reperfusion [16]. Thus, β1-AR blockade with esmolol during
early reperfusion can exert unopposed β2-AR stimulation via
endogenous epinephrine producing myocardial protection.
Reduction in myocardial oxygen consumption by esmolol
during ischemia can potentially contribute to LV-IS-reduction.
However, cardioprotection conferred by esmolol + milrinone
in the present study is unlikely due to its favorable
hemodynamic profile as reflected by the low BP-HR double
product, since esmolol alone which had comparable hemo-
dynamic effect only produced modest LV-IS-reduction. The
IS-reduction conferred by esmolol + milrinone can be
reasonably attributed to their effects against reperfusion
injury, since the drugs were given towards the very end of
ischemia and the beginning of reperfusion.
Administration of Rp-cAMPS or Akt-inhibitor increases
IS, compared with saline control. These data indicate that
there is a basal tonic PKA-Akt signaling during ischemia/
reperfusion in the heart. Disrupting this signaling pathway
can result in catastrophic reperfusion injury. In the presence
of Rp-cAMPS or Akt-inhibitor, esmolol/milrinone con-
ferred no IS-reduction. This finding indicates that mecha-
nism of esmolol/milrinone-induced heart protection is
mediated through the PKA/Akt signaling cascade. The
cardiac effects of Rp-cAMPS are unlikely to be non-
specific in the present study. Our data (Fig. 2) indicates that
Rp-cAMPS, in the absence of background extracellular
ligand-mediated PKA stimulation, acts no more than saline
on purified myocytes (depleted with ICA cells). In ICA
cell-free myocyte preparation, Rp-cAMPS abolished myo-
cyte protective effect conferred by terbutaline + CGRP, the
agonists of β2-AR/CGRP-receptors known to stimulate
PKA with IS reduction [6, 10]. These findings confirmed
the specificity of Rp-cAMPS on PKA’s inhibition and
confirmed in vivo data that cardioprotection conferred by
milrinone + esmolol is mediated specifically through the
activation of cAMP-PKA dependent signaling pathway.
There are limited clinical therapies to reduce reperfusion
injury in AMI [22]. Recent experiments demonstrated that
cardiac PKA activation using concomitant β2-AR/CGRP-
receptor stimulation with the receptor agonists (i.e., terbuta-
line and CGRP) at early reperfusion conferred additive
cardioprotection with a 74% LV-IS-reduction compared
with saline [10]. The present study investigates a more
distal signaling step (i.e., skipping β2-AR/CGRP-receptor-
G protein-coupling sequence) to directly activate down-
stream PKA. This strategy allows the most rapid PKA
activation at the earliest reperfusion time. Milrinone is
known to activate PKA in non-ischemic [13] and ischemic
myocardium [14]. Esmolol may indirectly activate PKA at
early reperfusion through enhanced endogenous β2-AR
stimulation. Esmolol + milrinone infusion at 5-min before
the onset of reperfusion offers a “priming” effect of PKA
Non-hypoxia Hypoxia/re-oxygenation
Saline Saline
Rp-cAMPS
Terbutaline+CGRP
**
Fig. 2 Effect of Rp-cAMPS on myocyte survival during hypoxia/re-
oxygenation in ICA cell-free ventricular myocyte culture. There is no
difference in myocyte survival rates between saline and Rp-cAMPS
groups (p = ns, n=6/group). Rp-cAMPS abolishes myocyte protective
effect conferred by PKA agonists (Terbutaline + CGRP). Hypoxia/re-
oxygenation markedly increases myocyte death rates compared with
non-hypoxic condition in ICA cell-free myocyte culture. **: p<0.01
* *
**
Fig. 3 Effects of reperfusion therapy with esmolol, milrinone or E +
M on LV myocardial tissue PKA during ischemia/reperfusion (n=6/
group). PKA activity in saline treated group is significantly lower than
all other groups. *: p<0.05, **: p<0.01
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zone. Even in the absence of collaterals to the ischemic
zone, the fully circulated drugs in the blood stream can
mount the quickest action upon reperfusion without missing
the critical first seconds of “window-of-opportunity”.
Antiapoptotic pathways involved in esmolol + milrinone-
mediated myocardial protection Milrinone increases cyto-
solic cAMP production which induces PKA activation [13,
14]. PKA activation can, in turn, activate Akt-dependent
antiapoptotic pathway [6, 23]. It is unclear why the level of
Akt activation is much more robust than those of PKA
activation in the present study. We speculated that myocar-
dial Akt activation may not be easily triggered at baseline
despite relatively high basal PKA activity in living animals.
Under extreme circumstances, further increase in PKA
activity beyond a critically high threshold may trigger
robust Akt activation. The present study has demonstrated
proof-of-the-concept that esmolol + milrinone-induced Akt
activation is dependent on PKA stimulation, since in the
presence of PKA inhibition with Rp-cAMPS, milrinone +
esmolol failed to activate Akt (Fig. 4). Furthermore, the
down stream Akt activation plays a critical role in
myocardial protection, since the inhibition of Akt abolished
esmolol + milrinone-induced myocardial protection. The
fact that the larger than control LV-IS following PKA or
Akt inhibition suggests that ischemia-reperfusion per se can
trigger a small but significant amount of PKA/Akt-
dependent antiapoptotic signaling which can be readily
enhanced pharmacologically during the very early phase of
reperfusion.
The β1-AR blocker is the standard of therapy for
patients with AMI to improve long-term survival [24–26].
The mechanisms underlying cardioprotection of β1-AR
blocker may not be simply attributed to its reducing
myocardial oxygen consumption or blocking β1-AR sig-
naling which is detrimental to the heart. It has been well
recognized that β1-AR and β2-AR signaling are counter-
regulatory [11, 12]. Myocardial β1-AR inhibition greatly
enhances cardioprotective β2-AR signaling which activates
antiapoptotic pathway [11, 12]. Selective β1-AR blockade
with esmolol significantly enhanced milrinone-mediated
myocardial protection. These results underscore the impor-
tance of intrinsic cardiac epinephrine-β2-AR signaling
derived from ICA cells providing rich myocardial epineph-
rine [5, 6]. Furthermore, our findings indicate that activa-
tion of β2-AR in concert with direct PKA activation with
milrinone confers powerful heart protection. Accumulating
evidence supports a concept that apoptosis contributes
substantially to the extent of IS in the reperfused AMI
[2]. In agreement with this, the ratios of IS-reduction
Rp-cAMPS
pAkt
Total Akt
AB
pAkt
Total Akt
*
*
*
*
Fig. 4 Panel A: Effects of reperfusion therapy with esmolol,
milrinone or E + M on myocardial tissue Akt activity during
ischemia/reperfusion (n=5/group). The pAkt activity in saline treated
group is significantly lower compared with all other group (**: p<
0.01). The phosphorylated Akt levels were normalized to total Akt.
Insert: an individual case of myocardial tissue pAkt levels in response
to different treatments. Panel B: A typical case demonstrating that in
the presence of PKA inhibitor Rp-cAMPS, E + M exerts no effect on
myocardial pAkt activity. Overall, application of E + M increases
myocardial pAkt activity by 7±1-fold, compared with saline (p<0.01,
n=4/group). In the presence of Rp-cAMPS, E + M has no effect on
myocardial tissue pAkt activity during ischemia/reperfusion, com-
pared with saline (n=4/group)
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Fig. 5 (a) Effects of reperfusion
therapy with esmolol, milrinone
or E + M on LV myocyte
apoptosis during ischemia/
reperfusion. Panels
A-C show a case of total
cardiocyte apoptosis in a
saline-treated heart.
A: Propidium iodide-positive
nuclei (red) of cardiocytes.
B: TUNEL-positive nuclei
(green, arrows) in the same
field. C: Superimposed panels A
and B. Panels D-F show a case
of cardiocyte apoptosis in an
E + M-treated heart.
D: Popidium iodide-positive
nuclei of cardiocytes.
E: TUNEL-positive nuclei in the
same field of D.
F: Superimposed panels D and
F. Panels
G-H: Immunohistochemical
double staining confirms
myocyte (red)-specific apoptosis
in a field of saline-treated heart
(G) and field esmolol +
milrinone-treated heart (H).
TUNEL positive nuclei are
stained with green color. Scale
bar=10 μm. (b). A: Percentage
changes in cardiocyte apoptosis
in the hearts treated with saline,
esmolol, milrinone and E + M,
respectively (n=6/group). The
cardiocyte apoptosis rate in
hearts treated with E + M is
smaller than all other groups
(p<0.01). B: Comparison of
myocyte-specific apoptosis
among 4 different treatment
groups. The extent of ventricular
myocyte apoptosis in esmolol +
milrinone group is significantly
smaller than all other groups
(p<0.01). *: p<0.05, **:
p<0.01
230 Cardiovasc Drugs Ther (2011) 25:223–232between esmolol + milrinone and other treatment groups
are in the similar orders of the rations of myocyte apoptosis
reduction in their counterparts. The absolute magnitudes of
apoptosis do not mach those of LV-IS. This discrepancy
might be due to several reasons. First, the immunostaining
might not be sensitive enough to detect all apoptotic nuclei,
especially those of early phase. Second, myocyte necrosis
certainly contributes to substantial amount of total LV-IS.
Nevertheless, the present study provides proof-of-the-
concept that anti-apoptotic effect elicited by esmolol +
milrinone contributes significantly to the reduced reperfu-
sion injury.
Perspectives There is no clinically approved drug that can
effectively reduce reperfusion injury during AMI. For non-
cardioprotective purpose, esmolol or milrinone was used
individually with good tolerance in patients with AMI with
or without reperfusion therapy [27, 28]. Although the
cardioprotective efficacy of combination therapy with
esmolol + milrinone has not been tested clinically, their
remarkable preclinical LV-IS-limiting effect, if confirmed in
human study, may make this novel combination a promis-
ing candidate for transition to the clinical arena.
Study limitation The present study cannot deduce that
cardioprotective results of esmolol+milrinone are class
effects of β1-AR blockers and PDE inhibitors. The reason
for selecting esmolol vs. other β1-selective AR blockers is
that esmolol possesses ultra short half-life providing
favorable hemodynamic profile when combined with
milrinone infusion. Further studies are needed to test
whether other β1-AR blockers and PDE inhibitors confer
similar cardioprotection. While the PKA phosphorylation
was used to determine PKA activity in the present study,
we have not assessed other molecular markers associated
with PKA activation such as cytosolic cAMP levels or
phosphorylation of the L-type calcium channels.
In conclusion, late-ischemia/early reperfusion therapy
with combination of esmolol + milrinone confers additive
LV-IS-reduction in experimental AMI. This cardioprotec-
tive effect is associated with a robust induction of
antiapoptotic signaling pathway.
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